From liver to life: The overlooked impact of MASLD on digestive cancer outcomes
Recommended Citation
Ismail M, Sardarova N, Kakakhel MZ, Singh P, Zaied MA, Ahmad H, Alsaadi MH, Ikram M, Riffat G, Barawi M. From liver to life: The overlooked impact of MASLD on digestive cancer outcomes. J Clin Oncol 2025; 43(16).
Document Type
Conference Proceeding
Publication Date
5-28-2025
Publication Title
J Clin Oncol
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is an increasing public health concern with the potential to increase the development of malignancy of the digestive tract and beyond. We aim to explore mortality trends of digestive cancer (DC) among MASLD patients. Methods: The CDC WONDER database was examined to extract age-adjusted mortality rates (AAMR) regarding DC among MASLD patients aged 25 years and older between 1999 and 2020. Data was stratified by age, gender, race, and U.S geographic regions. Results: 67616 deaths were documented from 1999 to 2020, with an overall AAPC of 2.8 (95% CI 1.99 to 3.62) and total AAMR of 13.6 (95%CI 13.5 to 13.7). Males showed higher mortality rates than females with an overall AAMR of 22.1 (95%CI 21.9 to 22.3). However, female gender showed higher AAPC with value of 3.6 (95%CI 2.88 to 4.32). Slight difference of AAPC between patients aged 55-64 and over 85 years as they showed the highest AAPC with value of 4.23 (95%CI 3.23 to 5.24) and 4.21 (95%CI 2.31 to 6.14) receptively. White race accounted for the highest AAPC followed by African American with 3.11 (95%CI 2.18 to 4.06) and 1.73 (95%CI 0.33 to 3.15) respectively. Conclusions: The highest AAPC was observed among Whites, older males, large central metropolitan residents and West residents. The observed disparities suggest the importance of improving outcomes for DC patients, particularly with MASLD. Keywords: Digestive cancer, MASLD, CDC WONDER, AAPC.
Volume
43
Issue
16
